Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cephalon, Inc.

http://www.cephalon.com

Latest From Cephalon, Inc.

EMA: Multiple COVID-19 Booster Programs ‘Not Sustainable’ In Long Term

Global regulators have been discussing how best to approach vaccination in the face of possible future coronavirus variants, and whether bivalent or multivalent vaccines could be the answer.

Europe Coronavirus COVID-19

‘Dangling’ Cancer Indications In US: New Year Brings New Withdrawals Of Accelerated Approvals

Gilead pulls Zydelig’s third-line indications in follicular B-cell lymphoma and small lymphocytic lymphoma due to confirmatory trial enrollment challenges resulting from an evolving treatment landscape; 13 cancer indications now have been withdrawn since the FDA began cracking down on accelerated approvals that have not confirmed clinical benefit.

Clinical Trials Review Pathway

Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate

Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.

Commercial Coronavirus COVID-19

Finance Watch: Mega-Rounds Add Up To Another Record Year For Biopharma VC Funding

Private Company Edition: NVCA and Pitchbook data show pharma and biotech companies raised $37.8bn in venture capital in 2021, up 41% from the record $26.8bn total in 2020. Recent mega-rounds include $190m for Maze and $200m for Alumis, and Sound Bioventures raised a €110m fund.

Financing Innovation
See All

Company Information

  • Other Names / Subsidiaries
    • Arana Therapeutics (Peptech and EvoGenix)
    • BioAssets Development Corporation
    • Ception Therapeutics
    • ChemGenex Pharmaceuticals Limited
    • CIMA Labs
    • Gemin X Pharmaceuticals
    • Zeneus Pharma
    • Mepha
UsernamePublicRestriction

Register